Liquidia faces new PH-ILD patent infringement suit from United Therapeutics on '327 Patent

Liquidia Corp

United Therapeutics filed amended complaint Nov 30, 2023, alleging YUTREPIA infringes new '327 Patent covering inhaled treprostinil for PH-ILD.
The '327 Patent issued Nov 28, 2023; Liquidia argues no 30-month stay because it issued after original NDA filing.
Ongoing IPR of '793 Patent: PTAB ruled claims unpatentable; appeal pending at Federal Circuit after Dec 4, 2023 oral argument.
Liquidia intends to vigorously defend; previous Hatch-Waxman ruling still blocks YUTREPIA approval for PH-ILD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.